Introduction: Pediatric Ketamine Use in Context
The application of low-dose ketamine in pediatric populations represents a domain of increasing clinical interest tempered by significant developmental pharmacological and safety considerations. Pediatric low-dose ketamine dosing requires appreciation of age-dependent differences in drug metabolism, body composition, receptor expression, and neurodevelopmental vulnerability that distinguish children and adolescents from adult patients (Anderson and Holford, 2013). While ketamine has a long history of use in pediatric anesthesia and procedural sedation -- predating its psychiatric applications by decades -- the translation of sub-anesthetic ketamine protocols from adult psychiatric and pain indications to younger populations demands careful evaluation of developmental pharmacokinetic profiles and age-specific safety data.
The clinical impetus for investigating ketamine in pediatric populations stems from the substantial burden of treatment-resistant depression, suicidal ideation, and chronic pain in children and adolescents, coupled with the limited efficacy and delayed onset of conventional treatments. Approximately 30-40% of adolescents with major depressive disorder fail to respond adequately to first-line SSRI therapy combined with psychotherapy. For an overview of how ketamine's mechanism addresses treatment resistance, see how ketamine works. (March et al., 2004). The prospect of a rapid-acting intervention for pediatric psychiatric emergencies -- particularly acute suicidal ideation -- has catalyzed research activity, though the evidence base remains substantially less developed than for adult populations.
Developmental Pharmacokinetics
Age-Dependent Metabolism
Ketamine metabolism undergoes significant developmental changes from infancy through adolescence. Hepatic cytochrome P450 enzyme systems -- particularly CYP3A4 and CYP2B6 -- exhibit age-dependent maturation patterns that directly influence ketamine clearance. CYP3A4 activity is reduced in neonates (approximately 30-50% of adult values), reaches adult levels by approximately 6 months of age, and may exceed adult activity during early childhood (1-4 years) before returning to adult levels in adolescence (Hines, 2007).
CYP2B6, the primary enzyme responsible for ketamine N-demethylation, follows a similar but distinct maturational trajectory. Expression is minimal at birth and increases progressively during the first year of life, reaching approximately 50-70% of adult levels by age 1 year and full maturation by approximately 5-7 years (Croom et al., 2009). These maturational kinetics have direct implications for ketamine dosing: neonates and young infants will exhibit reduced clearance and prolonged drug exposure relative to older children and adults at equivalent weight-based doses.
Grant and colleagues (1983) characterized ketamine pharmacokinetics in pediatric surgical patients, demonstrating that children aged 4-11 years exhibited higher weight-normalized clearance rates than adults, a pattern discussed further in the weight-based dosing guidelines, likely reflecting the enhanced CYP activity observed during early to middle childhood. This increased clearance translates to a shorter elimination half-life (approximately 1.5-2 hours in children versus 2-3 hours in adults) and may necessitate higher weight-based doses or shorter dosing intervals to achieve comparable systemic exposure.
Volume of Distribution
The apparent volume of distribution (Vd) of ketamine is influenced by body composition, which changes substantially across pediatric development. Neonates have higher total body water content (approximately 75% versus 60% in adults) and lower body fat percentage, resulting in a larger volume of distribution for lipophilic drugs on a weight-normalized basis. As body fat increases through infancy and early childhood, the Vd for lipophilic compounds like ketamine undergoes corresponding changes (Anderson and Holford, 2013). These pharmacokinetic differences mean that initial plasma concentrations following a weight-based bolus dose will be lower in very young children, potentially requiring adjustment of loading doses.
Metabolite Profiles
The ratio of ketamine to norketamine and hydroxynorketamine metabolites may differ in pediatric versus adult populations due to developmental enzyme kinetics. In particular, the production of (2R,6R)-HNK -- an active metabolite implicated in NMDA receptor-independent antidepressant activity -- is dependent on metabolic pathways that may not be fully mature in young children (Zanos et al., 2016). Whether pediatric patients generate sufficient HNK to replicate the metabolite-mediated therapeutic effects observed in adults represents an unresolved pharmacokinetic question with potential implications for efficacy.
Clinical Applications and Evidence
Pediatric Treatment-Resistant Depression
The clinical evidence for sub-anesthetic ketamine in pediatric depression is limited to case reports, case series, and a small number of open-label studies. Dwyer and colleagues (2021), in a comprehensive review published in Journal of the American Academy of Child and Adolescent Psychiatry, identified 13 published studies examining ketamine for depression in individuals under 18 years of age, encompassing approximately 100 total patients. The available data suggest antidepressant response rates broadly comparable to adult populations (approximately 40-70% response at 24-72 hours), though the methodological quality of included studies was predominantly low (uncontrolled designs, small samples).
A notable open-label study by Cullen and colleagues (2018), published in Journal of Child and Adolescent Psychopharmacology, examined six intravenous ketamine infusions (0.5 mg/kg over 40 minutes) in 13 adolescents (aged 12-18) with treatment-resistant depression. Significant improvement was observed on the Montgomery-Asberg Depression Rating Scale (MADRS) following the infusion series, with 38% meeting response criteria and 31% achieving remission. Dissociative side effects were transient and comparable in severity to those reported in adult trials.
Acute Suicidal Ideation in Adolescents
The potential for ketamine to provide rapid reduction of suicidal ideation in adolescents represents a particularly pressing clinical application. Adolescent suicide is a leading cause of death in the 10-24 age group, and the latency period of conventional antidepressants (4-6 weeks) represents a critical gap in acute management. Price and colleagues (2014) demonstrated rapid anti-suicidal effects of ketamine in adults, and extrapolation of these findings to adolescent populations has motivated pilot investigations.
Zarrinnegar and colleagues (2019) reported on a case series of intranasal ketamine for acute suicidal ideation in adolescent emergency department patients, describing rapid reduction in suicidality ratings within 60-120 minutes of administration. While these findings are preliminary and uncontrolled, they highlight the potential clinical utility and the urgent need for randomized controlled trials in this high-risk population.
Pediatric Chronic Pain
Ketamine has a more established evidence base in pediatric chronic pain management, particularly for complex regional pain syndrome (CRPS) in children and adolescents. Sheehy and colleagues (2015), reporting in Pediatrics, described outcomes of sub-anesthetic ketamine infusions in a pediatric pain rehabilitation program, demonstrating significant pain reduction and functional improvement. Pediatric CRPS responds to ketamine infusion protocols with efficacy comparable to adult populations, and some centers employ multi-day continuous infusion protocols for severe cases (Finkel et al., 2007).
Procedural Sedation Context
Ketamine's extensive safety record in pediatric procedural sedation (at doses of 1-2 mg/kg IV) provides valuable safety context for sub-anesthetic applications. Decades of use in emergency departments and procedural settings have established that ketamine is well-tolerated in children, with serious adverse events (laryngospasm, severe emergence reactions) occurring at rates below 1-2% (Green et al., 2011). While procedural sedation doses exceed the sub-anesthetic range, this safety database provides reassurance about the drug's fundamental tolerability in pediatric populations.
Dosing Recommendations and Protocols
Weight-Based Dosing in Children
The standard adult sub-anesthetic dose of 0.5 mg/kg IV over 40 minutes has been adopted for adolescent patients in most published studies, consistent with the principle that older children and adolescents have pharmacokinetic profiles approaching adult values. For younger children (under 12 years), some practitioners advocate starting at lower doses (0.25-0.4 mg/kg) and titrating based on response and tolerability, reflecting both the limited evidence base and the developmental pharmacokinetic considerations discussed above.
Oral and sublingual dosing in pediatric populations requires consideration of the same bioavailability challenges present in adults, with the additional complexity of weight-appropriate formulation volumes and palatability concerns. Compounded oral ketamine solutions can be flavored to improve acceptability, and dose ranges of 0.5-1.5 mg/kg orally have been used in pediatric pain studies (Hocking and Cousins, 2003).
Frequency and Duration of Treatment
No consensus exists regarding optimal treatment frequency or duration for pediatric sub-anesthetic ketamine. The adolescent depression studies have generally employed protocols adapted from adult paradigms -- typically three to six infusions over two to three weeks -- without systematic dose-finding or schedule optimization. Given the heightened neurodevelopmental considerations in pediatric populations, conservative approaches favoring the minimum effective number of treatments are advisable pending further safety data.
Safety and Neurodevelopmental Considerations
Neurotoxicity Concerns from Preclinical Data
The most significant safety concern regarding pediatric ketamine use derives from preclinical studies demonstrating neurotoxicity following prolonged or repeated anesthetic-dose ketamine exposure in developing animal brains. Ikonomidou and colleagues (1999), in a seminal study published in Science, demonstrated that NMDA receptor blockade during the synaptogenesis period triggered widespread neuronal apoptosis in the developing rat brain. Subsequent studies in non-human primates confirmed that prolonged ketamine exposure (24 hours of anesthetic-dose infusion) produced neuronal cell death and lasting cognitive deficits in neonatal rhesus macaques (Brambrink et al., 2012).
These findings must be interpreted cautiously in the context of clinical sub-anesthetic use. Critical differences include dose magnitude (anesthetic versus sub-anesthetic), exposure duration (hours of continuous exposure versus 40-minute infusions), developmental timing (neonatal versus adolescent), and species-specific vulnerabilities. The human brain's synaptogenesis period extends primarily through the first two years of life, and most psychiatric applications of sub-anesthetic ketamine target adolescents (12-18 years) -- well beyond this critical window. Nevertheless, the preclinical data mandate caution, particularly for applications in younger children and for repeated or prolonged dosing protocols.
Cognitive and Academic Monitoring
Long-term cognitive effects of repeated sub-anesthetic ketamine exposure in developing brains represent a significant knowledge gap. Neurocognitive testing -- encompassing domains of memory, attention, executive function, and processing speed -- should be incorporated into clinical monitoring protocols for pediatric patients receiving ketamine treatment. Validated pediatric neurocognitive batteries (such as the NIH Toolbox Cognition Battery) administered at baseline and at follow-up intervals can detect treatment-emergent cognitive changes (Dwyer et al., 2021).
Psychiatric Side Effects
Adolescent patients may exhibit different patterns of psychiatric side effects compared with adults. Emergence reactions -- including agitation, vivid hallucinations, and dysphoria -- occur at rates of approximately 5-15% in pediatric anesthetic populations and may be more distressing in the context of pre-existing psychiatric illness (Green et al., 2011). Careful pre-treatment psychoeducation, environmental optimization (quiet, dimly lit treatment rooms), and availability of benzodiazepine rescue are recommended.
Ethical and Regulatory Framework
Informed Consent and Assent
The off-label nature of sub-anesthetic ketamine for pediatric psychiatric indications necessitates a robust informed consent process involving both parents/guardians and, where developmentally appropriate, the minor patient's assent. The consent discussion should address the limited evidence base, the neurodevelopmental uncertainty, known acute side effects, and the alternatives available. Documentation of the informed consent process should be thorough and explicitly acknowledge the off-label status of the intervention.
Regulatory Considerations
Neither esketamine (Spravato) nor racemic ketamine has regulatory approval for any psychiatric indication in individuals under 18 years of age. The esketamine REMS program restricts use to adults, and off-label IV ketamine use in minors occurs entirely at the discretion of treating clinicians. The absence of regulatory framework for pediatric ketamine use underscores the need for institutional protocols, ethics committee oversight, and systematic data collection to support future regulatory evaluation.
Conclusion
Pediatric low-dose ketamine dosing requires careful integration of developmental pharmacokinetic principles, age-specific safety data, and a conservative clinical approach appropriate to the limited evidence base. While preliminary data suggest antidepressant efficacy in adolescents comparable to adults, the evidence base is insufficient to support routine clinical use outside of research settings or carefully monitored clinical programs. Neurodevelopmental safety concerns -- rooted in preclinical neurotoxicity data and the absence of long-term follow-up in human pediatric patients -- mandate a cautious, evidence-generating approach. Rigorously designed randomized controlled trials in adolescent depression and suicidal ideation, with comprehensive neurocognitive safety monitoring, represent the highest-priority research needs in this domain.
References
- AAP: American Academy of Pediatrics — Professional society providing pediatric clinical guidelines, safety standards, and drug use recommendations
- MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine medication information including pediatric use context
- PubMed: Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics — Pharmacokinetic review including developmental pharmacology considerations
- FDA MedWatch: Safety Information and Adverse Event Reporting — FDA safety reporting system for pediatric drug adverse events
Share